[Skip to Navigation]
Editorial
September 18, 2019

Predicting Clinical Responses to Ustekinumab: Progress Toward a Future of Personalized Medicine

Author Affiliations
  • 1Oregon Medical Research Center, Portland, Oregon
JAMA Dermatol. 2019;155(11):1227-1228. doi:10.1001/jamadermatol.2019.2587

In 2019, the efficacy and safety of biologic therapy offer most patients with psoriasis the opportunity to achieve safe and complete or nearly complete clearance of skin lesions.1-4 A major obstacle remains across the world, however, in getting access to the best psoriasis medications, owing to high cost and/or lack of adequate health insurance. Indeed, it is commonplace for insurance companies and national regulatory authorities to control use of biologics to reduce overall costs to health care. More specifically, patients with psoriasis often have to experience treatment failure with cheaper, less effective, and less safe nonbiologic drugs prior to gaining access to biologics.5 The use of older biologics, such as adalimumab and ustekinumab, is often required (because of their lower cost in some settings) prior to using newer biologics that target interleukin (IL)-17A or IL-23,5 which are generally more effective.1-4 Thus, the cost of health care often dictates therapeutic choices, rather than the physician and/or patient choosing what is best for the patient.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×